[go: up one dir, main page]

BR0318201A - regime de dosagem de fármaco antiinflamatório não-esteroidal - Google Patents

regime de dosagem de fármaco antiinflamatório não-esteroidal

Info

Publication number
BR0318201A
BR0318201A BRPI0318201-0A BR0318201A BR0318201A BR 0318201 A BR0318201 A BR 0318201A BR 0318201 A BR0318201 A BR 0318201A BR 0318201 A BR0318201 A BR 0318201A
Authority
BR
Brazil
Prior art keywords
inflammatory drug
steroidal anti
drug dosage
dosage regimen
steroidal
Prior art date
Application number
BRPI0318201-0A
Other languages
English (en)
Inventor
Cathy K Gelotte
Douglas R Hough
Gerard P Mcnally
Original Assignee
Mcneil Ppc Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc
Publication of BR0318201A publication Critical patent/BR0318201A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"REGIME DE DOSAGEM DE FáRMACO ANTIINFLAMATóRIO NãO-ESTEROIDAL". A presente invenção refere-se a um método de administração de fármacos antiinflamatórios não esteroidais, em particular, derivados de ácido propiónico, como ibuprofeno, ou acetaminofeno que é fornecido. Este método proporciona efeito terapêutico melhorado, em particular alívio de dor, durante períodos de tempo prolongados.
BRPI0318201-0A 2003-03-21 2003-03-21 regime de dosagem de fármaco antiinflamatório não-esteroidal BR0318201A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/008846 WO2004093864A1 (en) 2003-03-21 2003-03-21 Non-steroidal anti-inflammatory drug dosing regimen

Publications (1)

Publication Number Publication Date
BR0318201A true BR0318201A (pt) 2006-03-21

Family

ID=33308979

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0318201-0A BR0318201A (pt) 2003-03-21 2003-03-21 regime de dosagem de fármaco antiinflamatório não-esteroidal

Country Status (10)

Country Link
EP (1) EP1605929B1 (pt)
JP (1) JP2006514982A (pt)
KR (1) KR101113005B1 (pt)
CN (1) CN1758904A (pt)
AU (2) AU2003220467A1 (pt)
BR (1) BR0318201A (pt)
CA (2) CA2746531C (pt)
MX (1) MXPA05010010A (pt)
NO (1) NO20054646L (pt)
WO (1) WO2004093864A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2630955B1 (en) 2007-08-15 2021-09-22 Johnson & Johnson Consumer Inc. Immediate release and sustained release ibuprofen dosing regimen
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
CA2814057C (en) * 2010-11-04 2022-02-01 Aft Pharmaceuticals Limited Intravenous composition comprising paracetamol and ibuprofen
NZ712594A (en) * 2012-03-19 2016-09-30 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
EP3344241A4 (en) * 2015-09-01 2019-04-03 Wellesley Pharmaceuticals, LLC FORMULATIONS WITH DELAYED RELEASE, METHOD FOR THE PRODUCTION AND USE THEREOF
KR20220113567A (ko) 2021-02-05 2022-08-16 이광미 염증 질환의 개선용 조성물
KR20240044914A (ko) 2022-09-29 2024-04-05 이광미 금속 티오옥토일 히알루로네이트 복합체를 포함하는 염증 질환의 개선용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2998450A (en) 1958-05-19 1961-08-29 Warner Lambert Pharmaceutical Process of preparing nu-acetyl-p-amino phenol
GB1497044A (en) 1974-03-07 1978-01-05 Prodotti Antibiotici Spa Salts of phenyl-alkanoic acids
US4873231A (en) 1986-04-08 1989-10-10 Smith Walton J Decreasing the toxicity of an ibuprofen salt
CA2061520C (en) 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
IT1264855B1 (it) 1993-06-21 1996-10-17 Zambon Spa Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
IT1276689B1 (it) 1995-06-09 1997-11-03 Applied Pharma Res Forma farmaceutica solida ad uso orale

Also Published As

Publication number Publication date
KR20060005345A (ko) 2006-01-17
EP1605929B1 (en) 2014-04-23
NO20054646L (no) 2005-10-10
JP2006514982A (ja) 2006-05-18
CN1758904A (zh) 2006-04-12
MXPA05010010A (es) 2006-03-10
AU2010202751A1 (en) 2010-07-22
WO2004093864A1 (en) 2004-11-04
CA2746531C (en) 2016-06-28
AU2003220467A1 (en) 2004-11-19
KR101113005B1 (ko) 2012-02-24
CA2519772C (en) 2016-05-31
CA2746531A1 (en) 2004-11-04
EP1605929A1 (en) 2005-12-21
CA2519772A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
ATE247477T1 (de) Inhalierbare medizinische aerosolzubereitung zur behandlung oder verbeugung von schmerz
CY1110842T1 (el) Φαρμακευτικες συνθεσεις για τη συντονισμενη διανομη των μσαφ
MX2009005339A (es) Suspensiones analgesicas de liberacion modificada.
CY1117656T1 (el) Επιλογες θεραπειας για τη νοσο του fabry
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE476972T1 (de) Verwendung von valproinsäure zur topischen behandlung von leichter bis mittelschwerer akne vulgaris
CY1106430T1 (el) Φαρμακα για εισπνοη που πepιλαμβανουν βηταμιμητικα και αντιχολινepγικο
PL2043637T3 (pl) Sposoby i leki do podawania ibuprofenu
HRP20040944B1 (en) Medicaments containing betamimetic drugs and a novel anticholinesterase drug
EP1781277A4 (en) COMBINATION PREPARATION
BRPI0415628A (pt) suspensões analgésicas para liberação controlada
BR0318201A (pt) regime de dosagem de fármaco antiinflamatório não-esteroidal
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
DE602007012904D1 (de) Neue 2',3'-methylidenacetyladenosine prodrugs zur
BRPI0415630A (pt) suspensões analgésicas para liberação controlada
EA200500941A1 (ru) Средство для лечения болезней суставов
EA200401454A1 (ru) Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний
PE20040176A1 (es) Ambroxol para el tratamiento de dolores cronicos
PT1583525E (pt) Utilização de uma combinação de substâncias da síntese de porfirina, salicilatos e anti-oxidantes na fototerapia de doenças da pele e/ou das articulações
BRPI0503821A (pt) uso de antitripsina alfa-1 para a preparação de medicamentos para o tratamento de fibromialgia e método de tratamento
WO2008079818A3 (en) Intravenous administration of water soluble analgesic formulations
RU2002111320A (ru) Способ лечения заболеваний нервной системы
BR0312333A (pt) Terapia de combinação e agente para sua execução
WO2004110378A3 (en) Treatment alzheimer's disease with r(-) 2-arylproponic acid nsaid alone or in combination with selective cox-2 inhibitor
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA.INT.CI. A61K 31/192, A61K 31/195, A61K 31/38, A61K 31/40, A61P 29/00

Ipc: A61K 31/192 (2011.01), A61K 31/195 (2011.01), A61K

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8 E 13 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2622 DE 06-04-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.